Madrigal Pharmaceuticals, Inc.
MDGL
Kedudukan dalam Saham
#2021
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Harga Saham
$446.50
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$10.32B
Perubahan (1 hari)
-0.72%
Perubahan (1 tahun)
1.48%
Negara
US
Perdagangan Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Pendapatan untuk Madrigal Pharmaceuticals, Inc. (MDGL)
Pendapatan pada Jun 2026 TTM: $-325.10M
Menurut laporan kewangan terkini Madrigal Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-325.10M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-373.63M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-295.35M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Madrigal Pharmaceuticals, Inc. dari 2001 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-325.10M | -30.22% |
| 2024 | $-465.89M | 24.69% |
| 2023 | $-373.63M | 26.50% |
| 2022 | $-295.35M | 22.12% |
| 2021 | $-241.85M | 19.58% |
| 2020 | $-202.24M | 140.92% |
| 2019 | $-83.95M | 155.85% |
| 2018 | $-32.81M | 5.32% |
| 2017 | $-31.15M | 18.06% |
| 2016 | $-26.39M | -61.57% |
| 2015 | $-68.67M | -20.30% |
| 2014 | $-86.16M | -4.47% |
| 2013 | $-90.19M | 43.64% |
| 2012 | $-62.79M | 32.52% |
| 2011 | $-47.38M | 26.46% |
| 2010 | $-37.47M | -147.37% |
| 2009 | $79.09M | -185.39% |
| 2008 | $-92.62M | 45.87% |
| 2007 | $-63.50M | 7.38% |
| 2006 | $-59.13M | -14.14% |
| 2005 | $-68.86M | 49.92% |
| 2004 | $-45.93M | 64.77% |
| 2003 | $-27.88M | -48.71% |
| 2002 | $-54.35M | 0.00% |
| 2001 | 0.00 | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,722.57% |
US
|
|
| $-3.09B | 849.57% |
US
|
|
| $-4.02B | 1,135.39% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -700.02% |
NL
|
